온코닉테라퓨틱스

476060KOSDAQ

73.3 / 100

Reference Date: 2026-09-08

Financial Score25.0 / 40

News Sentiment21.3 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 15.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Onconic Therapeutics focuses on developing innovative drugs for unmet medical needs in gastroesophageal reflux disease and oncology, emphasizing cost-effective small-molecule compounds. Its key product, 'Zastaprazan,' a P-CAB mechanism drug, has completed Phase 3 trials and received approval, while its next-generation oncology candidate 'Nesuparib' is in various clinical trials.

Number of Employees

38people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

45.38Industry Average 15.000.0Point

3.0x industry avg (risky)

PBR

10.27Industry Average 1.200.0Point

8.6x industry avg (risky)

ROE

24.65Industry Average 8.007.0Point

3.1x industry avg (excellent)

Debt Ratio

0.06Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲259.8% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲363.0% (1-year basis)

ROE Trend

4.0 / 4

Detailed News Sentiment

13 totalPositive 13Neutral 0Negative 0Average Sentiment Score 85

Positive
온코닉 ‘자큐보’, 헬리코박터 제균치료 3상 승인…적응증 확대 속도
온코닉테라퓨틱스의 신약 '자큐보'가 헬리코박터 제균치료 적응증 확대를 위한 국내외 임상 시험 승인으로 긍정적인 시장 반응을 이끌어낼 것으로 예상된다.
Positive
온코닉테라퓨틱스 '자큐보' 헬리코박터 제균요법 임상 3상 돌입
온코닉테라퓨틱스의 자큐보가 헬리코박터 제균 임상 3상 시작으로 새로운 처방 영역 확보 기대.
Positive
온코닉테라퓨틱스 '자큐보', 실사용 연구 결과 국제학술지 게재
온코닉테라퓨틱스의 자큐보 치료제가 GERD 증상 개선에 효과적이고 높은 치료 만족도와 복약 순응도를 보여 실사용 연구 결과 국제 학술지 게재로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position5.0Point

52w mid range (42%)

Current 16,290Won52-week high 26,30052-week low 8,825

1-month return6.0Point

1m +15.94% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral독립이사의선임ㆍ해임또는중도퇴임에관한신고2026-09-03
Neutral투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)(자스타프라잔시트르산염) 기반 삼제요법의 헬리코박터 파일로리 양성 환자 대상 유효성 및 안전성 평가를 위한 제3상 임상시험계획승인(변경승인))2026-09-02
Neutral반기보고서 (2026.06)2026-08-12